RxDoctor Payments Data

Abhay Laddu, MD

Cardiovascular Disease · Lake St Louis, MONPI 1538298294

Payments from drug & device makers

$19,110in general payments, 2019–2025

Across 80 payments — averaging $238.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$16K
  • Abiomed$963
  • Abbott$846
  • Edwards Lifesciences$364
  • Cvrx, Inc.$159
  • Heartflow, Inc.$147
  • plus $475 from 6 others

What the payments were for

  • Speaking & faculty fees$14,55076%
  • Travel & lodging$1,1796%
  • Food & beverage$3,38118%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,110 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$168,401
Medicare patients
1,334
Services billed
2,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,482$1,389,047
EntrestoSacubitril/Valsartan450$445,637
FarxigaDapagliflozin Propanediol349$299,317
JardianceEmpagliflozin253$214,939
XareltoRivaroxaban169$175,047
Repatha SureclickEvolocumab71$52,507
BrilintaTicagrelor37$22,849
DapagliflozinDapagliflozin Propanediol26$16,968
Praluent PenAlirocumab19$9,791
Metoprolol Succinate792$9,654
Midodrine Hcl90$7,679
Ranolazine ErRanolazine78$7,455
Atorvastatin Calcium605$6,368
Losartan Potassium708$4,965
Amiodarone Hcl272$4,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$75$445,637450 claims
AstraZenecaFarxiga, Brilinta$125$322,166386 claims
Johnson & JohnsonXarelto$36$175,047169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Lake St Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →